The FDA approval adds an oral ALK2 inhibitor for patients aged 12 years and older with the ultra-rare genetic disorder fibrodysplasia ossificans progressiva.

The approval provides adults with fibrodysplasia ossificans progressiva with a new treatment option designed to reduce abnormal bone formation and disease flare-ups in an ultra-rare genetic disorder.